Formycon announces positive FYB206 biosimilar study
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Formycon AG (FYB)Formycon AG stock price live, this page displays ETR FYB stock exchange data. View the FYB premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Formycon AG real time stock price chart below.
What Is the Formycon AG Stock Price Today?
The Formycon AG stock price today is 51.10.
What Is the Stock Symbol for Formycon AG?
The stock symbol for Formycon AG is "FYB."
What Stock Exchange Does Formycon AG Trade On?
Formycon AG is listed and trades on the Xetra stock exchange.
Is Formycon AG a Good Stock to Buy?
Determining whether Formycon AG—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the FYB quote. (ISIN: DE000A1EWVY8)
What Is the Formycon AG Stock Price Today?
The Formycon AG stock price today is 51.10.
What Is the Stock Symbol for Formycon AG?
The stock symbol for Formycon AG is "FYB."
What Stock Exchange Does Formycon AG Trade On?
Formycon AG is listed and trades on the Xetra stock exchange.
Is Formycon AG a Good Stock to Buy?
Determining whether Formycon AG—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the FYB quote. (ISIN: DE000A1EWVY8)
51.10
0.00(0.00%)
Delayed Data
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
50.40
51.30
52 wk Range
37.65
59.40
FYB Scorecard
Full Analysis
Analysts anticipate sales decline in the current year
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
50.4051.30
52 wk Range
37.6559.40
Key Statistics
Edit
Fair Value
UnlockFair Value Upside
UnlockEPS Growth Forecast
UnlockN/A
(N/A)
Dividends Payment Streak
UnlockEBITDA
UnlockEV/EBITDA
UnlockBook Value / Share
UnlockFair Value
UnlockFair Value Upside
UnlockEPS Growth Forecast
UnlockN/A
(N/A)
Dividends Payment Streak
UnlockEBITDA
UnlockEV/EBITDA
UnlockBook Value / Share
UnlockFYB Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceFair Price
Upside
Technical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
86.56
Upside
+69.39%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to drop this year
- Formycon AG receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Formycon AG receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Formycon AG receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Formycon announces positive FYB206 biosimilar study
- Investing.com
- Formycon AG receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Formycon AG receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Formycon AG receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Formycon AG Company Profile
Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious retinal diseases, including diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranpoto, Uptera, and Ravegza names. The company’s pipeline includes FYB202, a biosimilar candidate for Stelara used in the treatment of Psoriasis, Crohn’s disease, and ulcerative colitis which has completed the Phase III clinical trial; and FYB203, a biosimilar candidate for Eylea that treats ophthalmology related diseases, including neovascular age-related macular degeneration that has completed Phase III clinical trials. It is also developing FYB206, a biosimilar candidate for Keytruda, for the treatment of immuno-oncology diseases; and FYB207, a SARS-CoV-2 blocker, an antiviral drug for the treatment of COVID-19. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.
Compare FYB to Peers and Sector
Metrics to compare | FYB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipFYBPeersSector | |
|---|---|---|---|---|
P/E Ratio | 14.1x | −1.0x | −0.7x | |
PEG Ratio | 0.06 | 0.00 | 0.00 | |
Price/Book | 1.6x | 2.4x | 2.6x | |
Price / LTM Sales | 14.8x | 7.8x | 3.2x | |
Upside (Analyst Target) | 74.9% | 232.5% | 44.1% | |
Fair Value Upside | Unlock | 8.4% | 8.2% | Unlock |
Analysts' Recommendations
9 Buy
0 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 86.56
(+69.38% Upside)
People Also Watch
FAQ
What Is the Formycon (FYB) Stock Price Today?
The Formycon stock price today is 51.10
What Stock Exchange Does Formycon Trade On?
Formycon is listed and trades on the Xetra stock exchange.
What Is the Stock Symbol for Formycon?
The stock symbol for Formycon is "FYB."
What Is the Formycon Market Cap?
As of today, Formycon market cap is 905.80M.
What is Formycon Earnings Per Share?
The Formycon EPS is 3.84.
What Is the Next Formycon Earnings Date?
Formycon will release its next earnings report on 23 Apr 2025.
From a Technical Analysis Perspective, Is FYB a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.